The results from a phase 3 trial showed that lonapegsomatropin, a once-weekly human growth hormone therapy, led to greater reduction in trunk fat mass and increase in total body lean mass compared to placebo. In a comparison with a once-daily therapy, lonapegsomatropin also provided similar body composition benefits. The therapy also had similar safety and tolerability to somatropin. These findings will be used to submit a supplemental Biologics License Application to the U.S. FDA. Additionally, an investigational agent was found to improve health and quality of life for children with achondroplasia in an open-label extension of a phase 2 trial.
Source link
Once-weekly human GH increases total body lean mass for adults with GH deficiency
